교수, M.D.,Ph.D.연세대학교
  임상약리
  세브란스병원 임상시험센터
  2228-1735
  kspark@yuhs.ac
 
 

 

1. K. Park and D.Z. D'Argenio. Stochastic control of pharmacodynamic processes with application to ergotamine. In D.Z. D'Argenio (ed.), Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Vol. 2, Plenum Press, New York, pp. 189-204, 1995

2. D.Z. D'Argenio and K. Park. Uncertain pharmacokinetic/ pharmacodynamic systems: Design, estimation and control. Control Eng. Practice 5:1707-1716, 1997

3. K. Park, D. Verotta, T.F. Blaschke and L.B. Sheiner. A semiparametric method for describing noisy population pharmacokinetic data. J. Pharmacokin. Biopharm. 25: 615-642, 1997

4. G.F. Vanhove, H. Kastrissios, J.M. Gries, D. Verotta, K. Park, A.C. Collier, K Squires, L.B. Sheiner, and T.F. Blaschke. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob. Agents Chemother 41:2428-32, 1997

5. K. Park, D. Verotta, S.K. Gupta and L.B. Sheiner. Passive versus electrotransport-facilitated transdermal absorption of ketorolac. Clin. Pharmacol. Ther. 63:303-315, 1998

6. K. Park, D. Verotta, S.K. Gupta and L.B. Sheiner. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J. Pharmacokin. Biopharm. 26: 471-492, 1998

7. M.E. Krecic-Shepard, K. Park, C. Barnas, J. Slimko, D.R. Kerwin and J.B. Schwartz. Race and sex influence clearance of nifedipine: Results of a population study. Clin. Pharmacol. Ther. 68: 130-42, 2000

8. K. Park and D.Z. D'Argenio. Control of Uncertain Pharmacodynamic Systems. In D.Z. D'Argenio (ed.), Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Vol. 3, Kluwer Academic Publishers, Norwell, MA, pp. 275-293, 2004

9. K. Park, E. J. Hur, K. W. Han, H. Y. Kil, T. H. Han, Bispectral Index Does Not Correlate With Observer Assessment of Alertness and Sedation Scores During 0.5% Bupivacaine Epidural Anesthesia with Nitrous Oxide Sedation, Anesth Analg 103(2):385-9, 2006

10. K. Park, Y. S. Kim, K. I. Kwon, M. S. Park, Y. J. Lee, K. H. Kim, A Randomized, Open-Label, Two-Period, Crossover Bioavailability Study of Two Oral Formulations of Tacrolimus in Healthy Korean Adults. Clin Ther 29(1): 154-162, 2007

11. J. H. Choi, Y. J. Lee, S. B. Jang, J. E. Lee, K. H. Kim, K. Park. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 64(2): 185-191, 2007

12. J. H. Choi, M. G. Lee, J. Y. Cho, J. E. Lee, K. H. Kim, K. Park, Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83(2): 251-257, 2008

13. J. H. Sohn, H. J. Choi, J. T. Lee, J. D. Lee, J. H. Kim, Y. M. Moon, K. Park, K. B. Park, E. Kim, N. C. Yoo, Phase II study of transarterial holmium-166-chitosan complex in patients with a single, large hepatocellular carcinoma. Oncology 76(1): 1-9, 2009

14. Y. S. Yim, J. S. Choi, S. B. Jang, G. T. Kim, K. Park, C. H. Kim, J. Cheon, D. G. Kim, Pharmacokinetic properties and tissue storage of FITC conjugated SA-MnMEIO nanoparticles in mice. Current Applied Physics 9: e304-e307 (June 2009)

15. H. C. Kim, Y. J. Cho, C. W. Ahn, K. Park, J. C. Kim, J. S. Nam, Y. S. Im, J. E. Lee,
S. C. Lee and H. K. Lee, Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabetic Medicine 26: 1228-34 (December 2009)

16. S. B. Jang, Y. J. Lee, L. A. Lim, K. M. Park, B. J. Kwon, J. S. Woo, Y. I. Kim, M. S. Park, K. H. Kim, K. Park, Pharmacokinetic Comparison of Controlled-Release and Immediate-Release Oral Formulations of Simvastatin in Healthy Korean Subjects: A Randomized, Open-label, Parallel-Group, Single- and Multiple-Dose Study. Clin Ther 32(1): 206-216 (January 2010).

17. D. W. Han, K. Park S. B. Jang, S. E. Kern, Modeling the Effect of Sevoflurane on corrected QT Prolongation: A Pharmacodynamic Analysis. Anesthesiology 113(4): 806-11 (October 2010)

18. S. J. Shin, H. C. Jeung, J. B. Ahn, S. Y. Rha, J. K. Roh, K. Park, D. H. Kim, C. Kim, H. C. Chung, A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 28(5): 650-58 (2010)

19. J. Y. Chung, S. B. Jang, Y. J. Lee, M. S. Park, K. Park, Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 51(1): 53-59 (January 2011)

20. S. K. Cho, J. S. Yoon, M. G. Lee, D. H. Lee, L. A. Lim, K. Park, M. S. Park, J. Y. Chung, Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin. Pharmacol. Ther. 89(3): 416-20 (March 2011)

21. S. B. Jang, Y. J. Lee, M. S. Park, Y. G. Song, J. H. Kim, H. K. Kim, B. S. Ahn, K. Park, Population pharmacokinetics of amikacin in Korean inpatients undergoing TDM. Int J Clin Pharmacol Ther 49(6): 371-381 (June 2011)

22. D. Lee, L. A. Lim, S. B. Jang, Y. J. Lee, J. Y. Chung, J. R. Choi, K. Kim, J. W. Park, H. Yoon, J. Lee, M. S. Park, K. Park, Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study. Clin Ther 33(12): 2038-2053 (December 2011).

23. S. J. Shin, J. B. Ahn, K. Park, Y. J. Lee, Y. S. Hong, T. W. Kim, H. R. Kim, S. Y. Rha, J. K. Roh, D. H. Kim, C. Kim, H. C. Chung. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest New Drugs 30(2): 672-80 (April 2012).

24. S. K. Cho, E. S. Oh, K. Park, M. S. Park, J. Y. Chung. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics 22(8): 598-605 (August 2012).

25. E. S. Oh, S. H. Lee, M. S. Park, K. Park, J. Y. Chung. Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers. Int J Clin Pharmacol Ther 50(9): 647-56 (September 2012).

26. H. Roh, H. Son, D. Lee, K. J. Yeon, H. S. Kim, K. Park. Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation with a Film Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, 2-Period, Cross-Over, and Single-Dose Study. Clin Ther 35(3): 205-214 (March 2013).

27. H. Son, H. Roh, D. Lee, H. Chang, J. Kim, C. Yun, K. Park. Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects. Clin Ther 35(7): 915-922 (July 2013).

28. Y. Kim, M. Son, D. Lee, H. Roh, H. Son, D. Chae, M. Y. Bahng, K. Park. Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study. Clin Ther 35(7): 934-940 (July 2013).

29. H. Son, D. Lee, L. A. Lim, S. B. Jang, H. Roh, K. Park. Development of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and Amlodipine. Drug Metab. Pharmacokinet. (in press).


30. Son H, Lee DH, Lim LAY, Jang SB, Roh HR, Park K: Development of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and Amlodipine. DRUG METABOLISM AND PHARMACOKINETICS 29(2): 120-128, 2014

31. Son MJ, Kim Y, Lee DH, Roh HR, Son H, Guk J, Jang SB, Nam SY, Park K: Pharmacokinetic Interaction between Rosuvastatin and Telmisartan in Healthy Korean Male Volunteers: A Randomized, Open-label, Two-period, Crossover, Multiple-dose Study. CLINICAL THERAPEUTICS 36(8): 1147-1158, 2014

32. Roh HR, Son H, Lee DH, Chang HC, Yun C, Park K: Pharmacokinetic Interaction between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects. CLINICAL THERAPEUTICS 36(8): 1159-1170, 2014

33. Lee DH, Roh HR, Son H, Jang SB, Lee S, Nam SY, Park K: Pharmacokinetic Interaction between Rosuvastatin and Metformin in Healthy Korean Male Volunteers: A Randomized, Open-label, 3-period, Crossover, Multiple-dose Study. CLINICAL THERAPEUTICS 36(8): 1171-1181, 2014

34.Lee D, Son H, Lim L, Park K: Population pharmacokinetic analysis of diurnal and seasonal variations of plasma concentrations of cilostazol in healthy volunteers. THERAPEUTIC DRUG MONITORING 36(6): 771-780, 2014

35. Chae DW, Son MJ, Kim Y, Son H, Jang SB, Seo JM, Nam SY, Park K: Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 53(10): 883-889, 2015

36. S. Y. Kim, D. W. Chae, Y. M. Chun, K. H. Jeong, K. Park and D. W. Han. Modelling of the Effect of End-Tidal Carbon Dioxide on Cerebral Oxygen Saturation in Beach Chair Position under General Anaesthesia. Basic & Clinical Pharmacology & Toxicology 119(1): 85-92 (July 2016)

37. M. Son, J. Guk, Y. Kim, D.W. Chae, Y. Heo, D. Soh, K. Park. Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Clin Ther 38(8): 1845-1857 (August 2016).

38. D. W. Chae, H. Son, J. Guk, C. Park, K. Park. Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: A Single-Dose, Randomized, Open-Label, 2-Part, 2-Period Crossover Study in Healthy Korean Subjects. Int J Clin Pharm Th 54(9): 698-704 (September 2016)

39. Y. A. Heo, N. Holford, Y. Kim, M. Son, K. Park. Quantitative Model for the Blood Pressure Lowering Interaction of Valsartan and Amlodipine. British Journal of Clinical Pharmacology 82 (6): 1557-1567 (December 2016)

40. K. Park. A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology. Yonsei Medical Journal 58(1): 1-8 (January 2017)

41. J. Guk, H. Son, D. W. Chae, K. Park. Quantitative assessment of food effect on the pharmacokinetics of nano-crystallized megestrol acetate. Basic & Clinical Pharmacology & Toxicology 120(3): 270-277 (March 2017)

42. D. W. Chae, M. Son, Y. Kim, H. Son, K. Park. Mechanistic Model for Blood Pressure and Heart Rate Changes Produced by Telmisartan in Human Beings. Basic & Clinical Pharmacology & Toxicology 122(1): 139-148 (January 2018)

43. D. Chae, C. M. Nam, J. H. Kim, C. K. Lee, S. S. Kim, H. S. Kim, M. Jung, J. H. Cheong, H. C. Chung, S. Y. Rha, K. Park. A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. The AAPS Journal 20(4):72 (May 2018)

44. D. Chae, K. Park. An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients. Journal of Pharmacokinetics and Pharmacodynamics 45(5): 721-731 (October 2018)

45. J. Guk, D. Chae, H. Son, J. Yoo, J. H. Heo, K. Park. Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke. British Journal of Clinical Pharmacology 84 (11): 2586-2599 (November 2018)

46. Y. S. Jung, D. Chae, K. Park. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men. Journal of Pharmaceutical Sciences 107 (12): 3171-3178 (December 2018)

 



 

1. 박경수. 국내인에서의 항생제 약동학 모델링: 아미카신의 적용 예. 감염과 화학요법. Vol.37 Supplement 1 May 2005: S34-S39

 
 
 
 
Copyright ⓒ 2016, Department of Pharmacology Yonsei University College of Medicine
03722 서울시 서대문구 연세로 50-1 연세대학교 의과대학 약리학교실 Tel : 02)2228-1730 Fax : 02)313-1894.. Contact to Webmaster